| Identification | Back Directory | [Name]
(2R,3S/2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (RaceMic Voriconazole) | [CAS]
188416-29-7 | [Synonyms]
3R)-2-(2
Voriconazole
PI-6
(2R,3R)-Voriconazole
4-triazol-1-yl)-2-butanol (RaceMic Voriconazole)
4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1
(2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2S,3R)-rel-2-(2,4-Difluorophenyl)-3-(5-fluoropyriMidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(R *, S *) 3- (5-fluoropyrimidin-4-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl ) -2-butanol
4-Pyrimidineethanol, α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βS)-rel-
(2R,3S/2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (RaceMic Voriconazole)
(2R, 3S/2S, 3R)-3-(5-Fluoropyrimidin-4-yl)-2-(2,4-difluorophyenyl)-1-(1H-1,2,4 triazol-1-yl) butan-2-ol {Racemic Voriconazole}
(2R,3S/2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (RaceMic Voriconazole)ChemicalBook | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C16H14F3N5O | [MDL Number]
MFCD09263753 | [MOL File]
188416-29-7.mol | [Molecular Weight]
349.31 |
| Hazard Information | Back Directory | [Description]
Voriconazole-d3(188416-29-7) is an Ergosterol biosynthesis inhibitor and a labeled form of Voriconazole. This mono triazole antifungal agent inhibits the growth of Candida, Cryptococcus, and Aspergillus species. Studies suggest that Voriconazole-d3 can be synthesized by modifying the structure of fluconazole. This antifungal agent functions by inhibiting cytochrome P450 dependent 14-α-sterol demethylase, which is responsible for the biosynthesis of Ergosterol. Furthermore, Voriconazole-d3 inhibits fungal growth, cell wall thinning, and cell membrane degradation. | [Uses]
Voriconazole is a triazole antifungal agent used primarily in the treatment or prevention of aspergillosis and candidal infections. Voriconazole therapy is associated with transient, asymptomatic serum aminotransferase elevations and is a known cause of clinically apparent acute drug induced liver injury. | [Application]
Voriconazole-d3 is derived from 2,4-Difluoro-α-(1H-1,2,4-triazolyl)acetophenone, which is an antifungal activity, particularly toward Candida albicans and Candida parapsilosis. | [References]
1. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
Belanger, P., et al. 1997. Antimicrob. Agents Chemother. 41: 1840-1842. PMID: 9257776
2. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
Marco, F., et al. 1998. Antimicrob. Agents Chemother. 42: 161-163. PMID: 9449278
3. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
Espinel-Ingroff, A. 1998. J. Clin. Microbiol. 36: 198-202. PMID: 9431946 |
|
|